Form 4: Charles River Laboratories Director Acquires Shares and Stock Options

Director Martin Mackay acquired common stock and stock options in Charles River Laboratories International, Inc. on May 13, 2024.

Summary

• On May 13, 2024, Martin Mackay, a director of Charles River Laboratories International, Inc., acquired 559 shares of common stock at $228.41 per share.
• Mackay also acquired 372 shares of common stock at the same price in lieu of director service fees for the term commencing May 8, 2024.
• Additionally, Mackay acquired 1,311 stock options with an exercise price of $228.41.
• The restricted stock units and stock options vest upon the earlier of May 13, 2025, or the business day prior to the Company's next annual meeting of shareholders.
• Following these transactions, Mackay directly owns 12,531 shares of common stock and 1,311 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction by a company insider. The acquisition of shares and options could be seen as a slightly positive signal, but it's not a major event.

Positives

• The director's acquisition of shares and stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting of restricted stock units and exercisability of stock options are contingent upon the earlier of May 13, 2025, or the business day prior to the Company's next annual meeting of shareholders.

Industry Context

This filing reflects routine transactions by a company insider, which are common in publicly traded companies. These transactions are often related to compensation packages and are subject to regulatory reporting requirements.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash, stock, and stock options.
• The vesting schedules for stock options and restricted stock units are typical, often tied to continued service or performance milestones.
• Comparing the size of the grant to those of directors at comparable companies such as Laboratory Corporation of America Holdings (LH) or Quest Diagnostics (DGX) would provide further context.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates